Loading
A phase 1/2 trial of Sotorasib in non-small-cell lung cancer and small-cell lung cancer, run by Verastem, Inc., active and no longer recruiting.
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients is a phase 1/2 interventional study registered as NCT05074810 by Verastem, Inc., with 153 participants planned, started 2022-04-12 and due to reach its primary completion in 2026-06. Interventions recorded: avutometinib and sotorasib, avutometinib and sotorasib and defactinib. Conditions listed: Non Small Cell Lung Cancer, KRAS Activating Mutation. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sotorasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer.
Shares Verastem Oncology, Small-cell lung cancer, Non-small-cell lung cancer.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Non-small-cell lung cancer.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Sotorasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Non-small-cell lung cancer.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Non-small-cell lung cancer.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Non-small-cell lung cancer.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/